Differentiating carcinoid syndrome from other diseases: Difference between revisions
No edit summary |
No edit summary |
||
Line 108: | Line 108: | ||
* Localization of carcinoid tumor | * Localization of carcinoid tumor | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
|Positron emission tomography-computed tomography (PET-CT) using 18-fluoro-dihydroxyphenylalanine | | | ||
* Positron emission tomography-computed tomography (PET-CT) using 18-fluoro-dihydroxyphenylalanine | |||
* Ki-67 labeling index | |||
| | | | ||
* Valve thickening with retraction and reduction in the mobility of the tricuspid valve | * Valve thickening with retraction and reduction in the mobility of the tricuspid valve | ||
* | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 259: | Line 262: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
* Right lower quadrant pain | * Right lower quadrant pain | ||
| style="background: #F5F5F5; padding: 5px;" |+/- | | style="background: #F5F5F5; padding: 5px;" | +/- | ||
| style="background: #F5F5F5; padding: 5px;" | - | | style="background: #F5F5F5; padding: 5px;" | - | ||
| - | | - | ||
Line 289: | Line 292: | ||
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Asthma exacerbation | | style="background: #DCDCDC; padding: 5px; text-align: center;" |Asthma exacerbation | ||
| | | | ||
| style="background: #F5F5F5; padding: 5px;" |- | | style="background: #F5F5F5; padding: 5px;" | - | ||
| style="background: #F5F5F5; padding: 5px;" |- | | style="background: #F5F5F5; padding: 5px;" | - | ||
| style="background: #F5F5F5; padding: 5px;" |- | | style="background: #F5F5F5; padding: 5px;" | - | ||
|<nowiki>+</nowiki> | |<nowiki>+</nowiki> | ||
|<nowiki>+</nowiki> | |<nowiki>+</nowiki> | ||
| | | | ||
| style="background: #F5F5F5; padding: 5px;" | + | | style="background: #F5F5F5; padding: 5px;" | + | ||
| style="background: #F5F5F5; padding: 5px;" |- | | style="background: #F5F5F5; padding: 5px;" | - | ||
| style="background: #F5F5F5; padding: 5px;" |- | | style="background: #F5F5F5; padding: 5px;" | - | ||
|<nowiki>+</nowiki> | |<nowiki>+</nowiki> | ||
|<nowiki>-</nowiki> | |<nowiki>-</nowiki> |
Revision as of 16:25, 12 February 2019
Carcinoid syndrome Microchapters |
Diagnosis |
---|
Treatment |
Case Studies |
Differentiating carcinoid syndrome from other diseases On the Web |
American Roentgen Ray Society Images of Differentiating carcinoid syndrome from other diseases |
FDA on Differentiating carcinoid syndrome from other diseases |
CDC on Differentiating carcinoid syndrome from other diseases |
Differentiating carcinoid syndrome from other diseases in the news |
Blogs on Differentiating carcinoid syndrome from other diseases |
Risk calculators and risk factors for Differentiating carcinoid syndrome from other diseases |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Parminder Dhingra, M.D. [2]
Overview
Carcinoid syndrome must be differentiated from systemic mastocytosis, medullary thyroid carcinoma, irritable bowel syndrome, malignant neoplasms of the small intestine, benign cutaneous flushing, and recurrent idiopathic anaphylaxis.
Differentiating Carcinoid Syndrome from other Diseases
Carcinoid syndrome must be differentiated from:[1]
- Systemic mastocytosis
- Medullary thyroid carcinoma
- Irritable bowel syndrome
- Malignant neoplasms of the small intestine
- Benign cutaneous flushing
- Recurrent idiopathic anaphylaxis
On the basis [symptom 1], [symptom 2], and [symptom 3], [disease name] must be differentiated from [disease 1], [disease 2], [disease 3], [disease 4], [disease 5], and [disease 6].
Diseases | Clinical manifestations | Para-clinical findings | Gold standard | Additional findings | |||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Symptoms | Physical examination | ||||||||||||||||||||||||
Lab Findings | Imaging | Histopathology | |||||||||||||||||||||||
Abdominal pain | Diarrhea | Flushing | Dyspnea | Palpitations | Other symptoms | Wheezing | Telangiectasia | Hypotension | Tachycardia | Systolic murmur of tricuspid regurgitation | Other physical findings | Urinary 5-hydroxyindoleacetic acid (5-HIAA) | Serum Chromogranin A (CgA) | Other markers | Abdominal computed tomography (CT) | MRI | Somatostatin receptor scintigraphy [SRS], or Octreoscan | Metaiodobenzylguanidine (MIBG) scintigraphy | Other diagnostic studies |
| |||||
Carcinoid Syndrome[2][3][4] | +
Mild |
+
|
+ | + | + |
Dermatitis Diarrhea Dementia |
+ | + | + | + | + | + |
|
+
|
|
|
|
Pathognomonic radiological sign of midgut NET. | |||||||
Irritable Bowel Syndrome |
|
- | - | ||||||||||||||||||||||
Systemic mastocytosis | - | ||||||||||||||||||||||||
Malignant neoplasms of small intestine | |||||||||||||||||||||||||
Benign cutaneous flushing | |||||||||||||||||||||||||
Recurrent idiopathic anaphylaxis | |||||||||||||||||||||||||
Crohn disease |
|
+/- | - | - | - |
|
- | - |
|
Endoscopy | |||||||||||||||
Asthma exacerbation | - | - | - | + | + | + | - | - | + | - | - | - | Chest X ray | ||||||||||||
Acute Urticaria | |||||||||||||||||||||||||
Anaphylaxis | |||||||||||||||||||||||||
Angioedema | |||||||||||||||||||||||||
Drugs causing flushing |
| ||||||||||||||||||||||||
References
- ↑ Metcalfe DD (2000). "Differential diagnosis of the patient with unexplained flushing/anaphylaxis". Allergy Asthma Proc. 21 (1): 21–4. PMID 10748948.
- ↑ Rubin de Celis Ferrari AC, Glasberg J, Riechelmann RP (August 2018). "Carcinoid syndrome: update on the pathophysiology and treatment". Clinics (Sao Paulo). 73 (suppl 1): e490s. doi:10.6061/clinics/2018/e490s. PMC 6096975. PMID 30133565.
- ↑ Hegyi J, Schwartz RA, Hegyi V (January 2004). "Pellagra: dermatitis, dementia, and diarrhea". Int. J. Dermatol. 43 (1): 1–5. PMID 14693013.
- ↑ Savelli G, Lucignani G, Seregni E, Marchianò A, Serafini G, Aliberti G, Villano C, Maccauro M, Bombardieri E (May 2004). "Feasibility of somatostatin receptor scintigraphy in the detection of occult primary gastro-entero-pancreatic (GEP) neuroendocrine tumours". Nucl Med Commun. 25 (5): 445–9. PMID 15100502.